Albert bourla - Latest News Update, Information, Photos & Videos on Albert bourla at Lokmat Times

Pharmaceutical compes -- Pfizer and BioNTech -- announced on Thursday morning that real-world evidence from the Israel Ministry of Health show that there have been "dramatically" fewer Covid-19 cases and deaths among people in Israel who have been fully vaccinated with the Pfizer/BioNTech vaccine compared with those who have been not vaccinated.CNN citing Pfizer and BioNTech's announcement reported that the latest analysis from the Israel Ministry of Health shows that two weeks after the second dose, vaccine effectiveness was at least 97 per cent in preventing symptomatic disease, hospitalizations and death. The analysis also found that the vaccine effectiveness was 94 per cent in preventing asymptomatic Covid-19, where infections show no symptoms."We are extremely encouraged that the real-world effectiveness data coming from Israel are confirming the high efficacy demonstrated in our Phase 3 clinical trial and showing the significant impact of the vaccine in preventing severe disease and deaths due to COVID-19," said Luis Jodar, Senior Vice President & Chief Medical Officer, Pfizer Vaccines."The findings which suggest that the vaccine may also provide protection against asymptomatic SARS-CoV-2 infections are particularly mengful as we look to disrupt the spread of the virus around the globe. Altogether, these data are critical to understanding the role of vaccination in combatting the pandemic and provide hope to other countries dealing with this devastating disease, which has now afflicted the world for more than a year."SARS-CoV-2 is the name of the virus that causes Covid-19.According to CNN, The announcement comes about two weeks after a study published in the New England Journal of Medicine finding that the risk of symptomatic Covid-19 - meng people who were infected with the coronavirus and felt sick - decreased by 94 per cent among those who received two doses of the vaccine. Even before the second dose, the vaccine's effectiveness approached 60 per cent."This clearly demonstrates the power of the COVID-19 vaccine to fight this virus and encourages us to continue even more intensively with our vaccination campaign. We aim to achieve even higher uptake in people of all ages, which gives us hope of regaining normal economic and social function in the not so distant future," Yeheskel Levy, Israel Ministry of Health director, said in the announcement, as quoted by CNN."When we started our development last year in January, our aim was to make a difference for people worldwide and to help end this pandemic," Dr Ugur Sahin, co-founder and CEO of BioNTech, said in the announcement and added, "One year after the declaration of a pandemic by the WHO, we now see that we are on the right track to accomplish our goals."Albert Bourla, CEO of Pfizer, said data from Israel that shows the Pfizer/BioNTech vaccine prevents asymptomatic infection and death is a message of hope one year on from the declaration of a pandemic."It is a great opportunity, I think, that on this day of the first anniversary of the declaration of a pandemic, we do have a message of hope," Bourla told CNBC as reported by CNN.Bourla said that this is important for society, "because the asymptomatic carriers, the asymptomatic patients are the ones that they are spreading the disease mainly." "This is the first time that we are coming with a confirmation of a real-world evidence study of that magnitude," he said.( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Albert BourlaFOLLOW

Albert bourla, Latest News

India is currently dealing with a devastating second Covid-19 wave that has swept through the nation, crushing the country's ... ...

Pfizer CEO Albert Bourla has said that an oral drug for treating coronavirus could be ready next year adding the company is working on two antivirals, an oral and an injectable. ...

Pfizer's CEO Albert Bourla on Thursday that COVID-19 vaccine recipients will "likely" need a third dose between six to 12 months after they're fully vaccinated and suggested vaccinations for coronavirus could be needed every year. ...

Pfizer's CEO Albert Bourla on Thursday that COVID-19 vaccine recipients will "likely" need a third dose between six to 12 months after they're fully vaccinated and suggested vaccinations for coronavirus could be needed every year. ...

Pfizer and BioNTech requested the US Food and Drug Administration (FDA) on Friday for an amendment to its emergency use authorization of its Covid-19 vaccine, to expand its use for children ages 12 to 15 in the United States. ...

The ongoing Phase 3 clinical trial of Pfizer/BioNTech's coronavirus vaccine has confirmed its protection lasts at least six months after the second dose. ...

Pfizer-BioNTech Covid vaccine is extremely effective in adolescents between 12 to 15 years old, perhaps even more than in adults, the companies reported on Wednesday. ...

Pharmaceutical companies -- Pfizer and BioNTech -- announced on Thursday morning that real-world evidence from the Israel Ministry of Health show that there have been "dramatically" fewer Covid-19 cases and deaths among people in Israel who have been ...